Variable Loop Glycan Dependency of the Broad and Potent HIV-1-Neutralizing Antibodies PG9 and PG16

被引:194
作者
Doores, Katie J. [1 ,2 ,3 ]
Burton, Dennis R. [1 ,2 ,3 ]
机构
[1] Scripps Res Inst, Dept Immunol & Microbial Sci, La Jolla, CA 92037 USA
[2] Scripps Res Inst, IAVI Neutralizing Antibody Ctr, La Jolla, CA 92037 USA
[3] Massachusetts Gen Hosp, MIT, Ragon Inst, Boston, MA 02114 USA
基金
美国国家卫生研究院;
关键词
HUMAN-IMMUNODEFICIENCY-VIRUS; N-LINKED GLYCOSYLATION; BUTYLDEOXYNOJIRIMYCIN-MEDIATED INHIBITION; TYPE-1 ENVELOPE GLYCOPROTEIN; COMPLEMENT COMPONENT C3; SITE-SPECIFIC ANALYSIS; NEUTRALIZING ANTIBODIES; SYNCYTIUM FORMATION; AIDS VACCINE; BINDING-SITE;
D O I
10.1128/JVI.00552-10
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
The HIV-1-specific antibodies PG9 and PG16 show marked cross-isolate neutralization breadth and potency. Antibody neutralization has been shown to be dependent on the presence of N-linked glycosylation at position 160 in gp120. We show here that (i) the loss of several key glycosylation sites in the V1, V2, and V3 loops; (ii) the generation of pseudoviruses in the presence of various glycosidase inhibitors; and (iii) the growth of pseudoviruses in a mutant cell line (GnT1(-/-)) that alters envelope glycosylation patterns all have significant effects on the sensitivity of virus to neutralization by PG9 and PG16. However, the interaction of antibody is not inhibited by sugar monosaccharides corresponding to those found in glycans on the HIV surface. We show that some of the glycosylation effects described are isolate dependent and others are universal and can be used as diagnostic for the presence of PG9 and PG16-like antibodies in the sera of HIV-1-infected patients. The results suggest that PG9 and PG16 recognize a conformational epitope that is dependent on glycosylation at specific variable loop N-linked sites. This information may be valuable for the design of immunogens to elicit PG9 and PG16-like antibodies, as well as constructs for cocrystallization studies.
引用
收藏
页码:10510 / 10521
页数:12
相关论文
共 63 条
  • [31] LEONARD CK, 1990, J BIOL CHEM, V265, P10373
  • [32] Progress and obstacles in the development of an AIDS vaccine
    Letvin, Norman L.
    [J]. NATURE REVIEWS IMMUNOLOGY, 2006, 6 (12) : 930 - 939
  • [33] Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies
    Li, M
    Gao, F
    Mascola, JR
    Stamatatos, L
    Polonis, VR
    Koutsoukos, M
    Voss, G
    Goepfert, P
    Gilbert, P
    Greene, KM
    Bilska, M
    Kothe, DL
    Salazar-Gonzalez, JF
    Wei, XP
    Decker, JM
    Hahn, BH
    Montefiori, DC
    [J]. JOURNAL OF VIROLOGY, 2005, 79 (16) : 10108 - 10125
  • [34] GLYCOSYLATION IS NECESSARY FOR THE CORRECT FOLDING OF HUMAN IMMUNODEFICIENCY VIRUS-GP120 IN CD4 BINDING
    LI, Y
    LUO, LZ
    RASOOL, N
    KANG, CY
    [J]. JOURNAL OF VIROLOGY, 1993, 67 (01) : 584 - 588
  • [35] Removal of a single N-linked glycan in human immunodeficiency virus type 1 gp120 results in an enhanced ability to induce neutralizing antibody responses
    Li, Yun
    Cleveland, Bradley
    Klots, Igor
    Travis, Bruce
    Richardson, Barbra A.
    Anderson, David
    Montefiori, David
    Polacino, Patricia
    Hu, Shiu-Lok
    [J]. JOURNAL OF VIROLOGY, 2008, 82 (02) : 638 - 651
  • [36] V2 loop glycosylation of the human immunodeficiency virus type 1 SF162 envelope facilitates interaction of this protein with CD4 and CCRS receptors and protects the virus from neutralization by anti-V3 loop and anti-CD4 binding site antibodies
    Ly, A
    Stamatatos, L
    [J]. JOURNAL OF VIROLOGY, 2000, 74 (15) : 6769 - 6776
  • [37] Mascola JR, ANN REV IMMUNOL, V28, P413
  • [38] N-linked glycosylation of the V3 loop and the immunologically silent face of gp120 protects human immunodeficiency virus type 1 SF162 from neutralization by anti-gp120 and anti-gp41 antibodies
    McCaffrey, RA
    Saunders, C
    Hensel, M
    Stamatatos, L
    [J]. JOURNAL OF VIROLOGY, 2004, 78 (07) : 3279 - 3295
  • [39] HIV vaccines
    McMichael, Andrew J.
    [J]. ANNUAL REVIEW OF IMMUNOLOGY, 2006, 24 : 227 - 255
  • [40] Montefiori David C, 2005, Curr Protoc Immunol, VChapter 12, DOI 10.1002/0471142735.im1211s64